Medical device firm Somna Therapeutics has received approval from the US Food and Drug Administration (FDA) for its Reza Band upper esophageal sphincter (UES) Assist Device.
The new externally-worn, non-medication and non-surgical medical device has been developed to reduce symptoms of laryngopharyngeal reflux (LPR) by arresting regurgitation of stomach contents through the upper esophageal sphincter (UES).
Somna Therapeutics president and CEO Nick Maris said: "The FDA clearance of the REZA BAND is a significant milestone for Somna Therapeutics and for those suffering from acid reflux into the throat and lungs.
"The first-of-its-kind REZA BAND provides significant improvement in symptoms that are typical when stomach contents enter the throat and lungs."
The new device offers relief from LPR symptoms by applying slight external pressure to the cricoid cartilage area located below the Adam’s apple which increases the internal pressure of the UES.
It helps in reducing challenging symptoms, including chronic throat irritation and cough, hoarse voice, difficulty swallowing, and postnasal drip with few mild and short side effects.
Image: Somna Therapeutics has received FDA approval for Reza Band UES Assist Device. Photo: courtesy of PRNewswire/ Somna Therapeutics.